Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6518
    -0.0017 (-0.26%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    108,772.81
    +2,348.51 (+2.21%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6038
    +0.0007 (+0.12%)
     
  • AUD/NZD

    1.0903
    +0.0023 (+0.21%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     

Antibody Drug Conjugates Market Report 2021-2031

Forecasts by Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), by Payload Type (MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), by Target Antigen (CD30, HER2, CD22, CD33), by Drug Type (Adcetris, Kadcyla, Other Drugs), by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Application), by Linker Type (VC, VA, SMCC, Hydrazone, Other Linker Type).

New York, April 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antibody Drug Conjugates Market Report 2021-2031" - https://www.reportlinker.com/p06058459/?utm_source=GNW
PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) AND Profiles of Leading Companies, Region and Country

The analyst has estimated that the total market for Antibody Drug Conjugates would be around $xx billion in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Shouldn’t you be part of this market?

Antibody drug conjugate (ADC) technology continues to evolve as a widely successful drug targeting technology for the treatment of cancer. Advances in targeting antibodies, potent payloads and drug-linker technologies that facilitate improved ADC stability, potency and targeting efficiency led to the development of ten commercially viable ADCs. Shouldn’t you be part of this innovative market?

Antibody Drug Conjugates Market – Our new market research study shows trends, developments, progress in R&D and forecast revenue till 2031. The study offers YOU an in-depth assessment of competitors journeys within the market and its segments.

This report tell you how to stay ahead
Almost 600 tables and graphs are included in our just 500-page report. Read about the most lucrative industries and the future prospects on the market. Our new study allows you to evaluate forecast sales worldwide and regional. See financial results, trends, opportunities and forecasts of revenue. In this growing Antibody Drug Conjugates market a lot of opportunity remains. See how opportunities can be taken advantage of.

What are the key factors to reshaping the growth of the Antibody Drug Conjugates market? You must read this new report immediately. This exclusive report shows you potential revenue opportunity pool until 2031 for the assessment of data, trends, opportunities and business outlooks.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

How Increased Research on ADC Development Will Help the Market to Grow?

ADC Industry Involves a Specialization Business Model – be part of its success.

Will Innovation in ADCs Disrupt the Market in Future?
• Use of known or approved antibodies and cytotoxins in ADCs means potentially streamlined reviews and briefer development cycles.
• Technological advances, including stable linker technologies, have provided the impetus to develop more targeted and efficacious ADCs.
• Development of more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have an improved safety/efficacy profile.
• Increasing incidence of cancer is also contributing to the development of ADCs.

Is Complexity of ADCs hindering its Growth?
Manufacturing an ADC is a complex process. It requires a small molecule, an antibody, chemical linking chemistry and different amino acid conjugation. Antibody drug conjugates exhibit a more complex and heterogeneous structure than the parent monoclonal antibody. This complexity and heterogeneity present a significant challenge for generic manufacturers to copy the ADCs; thus, the complexity of ADCs preserves companies’ investment longer.

Forecasts to 2031 and other analyses reveal the commercial prospects of Antibody Drug Conjugates Market
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the Antibody Drug Conjugates market and submarkets

Global Antibody Drug Conjugates Market by Technology
Cleavable Linkers
Non-Cleavable Linkers
Other Technology
Global Antibody Drug Conjugates Market by Payload Type
MMAE
DM4
Camptothecin
DM1
MMAF
Other Payload Type

Global Antibody Drug Conjugates Market by Target Antigen
CD30
HER2
CD22
CD33

Global Antibody Drug Conjugates Market by Drug Type
Adcetris
Kadcyla
Other Drugs

Global Antibody Drug Conjugates Market by Application
Blood Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumor
Other Application

Global Antibody Drug Conjugates Market by Linker Type
VC
VA
SMCC
Hydrazone
Other Linker Type

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

• North America Antibody Drug Conjugates Market Outlook
o U.S. Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Canada Antibody Drug Conjugates Market Forecast & COVID Impact Analysis

• Europe Antibody Drug Conjugates Market Outlook
o Germany Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o France Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o United Kingdom Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Italy Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Russia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Europe Market Forecast & COVID Impact Analysis

• Asia Pacific Antibody Drug Conjugates Market Outlook
o China Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Japan Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o India Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Australia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o South Korea Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Asia Pacific Market Forecast & COVID Impact Analysis

• Latin America Antibody Drug Conjugates Market Outlook Market Forecast & COVID Impact Analysis
o Brazil Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Mexico Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Latin America Market Forecast & COVID Impact Analysis

• Middle East and Africa Antibody Drug Conjugates Market Outlook
o Saudi Arabia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o South Africa Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o UAE Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
o Rest of Middle East and Africa

Leading companies and the potential for market growth
AbbVie Inc.
Astellas Pharma Inc
Bayer Pharmaceuticals
Celldex Therapeutics, Inc.
Genentech Biotechnology
ImmunoGen Biotechnology
Immunomedics Inc
Lonza Group AG (Lonza)
Mersana Therapeutics Inc.
Takeda Pharmaceutical Company Limited
Roche Holding AG (Roche)
Pfizer Inc. (Pfizer)
Lantheus Holdings, Inc.
Seattle Genetics, Inc.
Merck KGaA

Overall world revenue for Antibody Drug Conjugates Market will surpass $xx billion in 2020, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Key Questions Answered in the report
• What are the best investment options for venturing into new product and service lines?
• What value proposals should businesses aim at while providing new funding for research and development?
• Which regulations will be most useful for stakeholders to enhance their supply chain network?
• Which regions could see demand ripening in certain segments in the near future?
• What are some of the best cost optimization strategies with vendors that some well-trained players have been successful with?
• What are the key perspectives that C-suite is leveraging to move businesses to a new growth trajectory?
• Which government regulations could call into question the status of key regional markets?
• How will the emerging political and economic scenario affect opportunities in key areas of growth?
• What are some of the value-added opportunities in different segments?
• What will be the barriers to entry for new players on the market?

How the Antibody Drug Conjugates Market report helps you?
In summary, our 490+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for Antibody Drug Conjugates Market, with forecasts for Technology, Linker Type, Drug Type, Payload Type, Application each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antibody Drug Conjugates market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Russia, Germany, France, UK, Italy, China, India, Japan, Korea and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Antibody Drug Conjugates Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Read the full report: https://www.reportlinker.com/p06058459/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001